Company Description
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections.
Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S.
aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia.
The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S.
aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11.
In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1.
The company was founded in 2003 and is headquartered in Los Gatos, California.
| Country | Canada |
| Founded | 2003 |
| IPO Date | Aug 10, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Dr. Vu L. Truong Ph.D. |
Contact Details
Address: 983 University Avenue, Bldg. B Los Gatos, California 95032 United States | |
| Phone | (408) 385-1742 |
| Website | aridispharma.com |
Stock Details
| Ticker Symbol | ARDS |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001614067 |
| CUSIP Number | 040334104 |
| ISIN Number | US0403341045 |
| Employer ID | 32-0074500 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Eric J. Patzer Ph.D. | Founder and Executive Chairman |
| Dr. Vu L. Truong Ph.D. | Founder, Chief Executive Officer, Chief Scientific Officer and Director |
| Dr. Hasan Jafri M.D. | Chief Medical Officer |
| Tamara S. Allen | Vice President of Finance |
| Jeffrey J. Fessler Esq., J.D. | Acting General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 16, 2024 | 8-K | Current Report |
| Dec 18, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 18, 2023 | 8-K | Current Report |
| Dec 15, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 6, 2023 | 10-Q | Quarterly Report |
| Nov 3, 2023 | 8-K | Current Report |
| Nov 3, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 3, 2023 | ARS | Filing |